Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare “Average Sales Price” Rule Predicts $800 Mil. In Savings For 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS expects the shift from average wholesale price-based reimbursement to the ASP plus 6% formula to generate savings of $530 mil. to Medicare and $270 mil. to beneficiaries in 2005. The agency expects changes outlined in its proposed rule to bring “transparency and appropriateness” to its payments for Part B drugs.

You may also be interested in...



Bristol To Sell Oncology Distribution Unit Ahead Of Medicare Part B Changes

The company has signed an agreement to sell its Oncology Therapeutics Network to One Equity Partners, Bristol announces. The transaction is expected to close during the first quarter of 2005.

Bristol To Sell Oncology Distribution Unit Ahead Of Medicare Part B Changes

The company has signed an agreement to sell its Oncology Therapeutics Network to One Equity Partners, Bristol announces. The transaction is expected to close during the first quarter of 2005.

CMS Expects No Significant Change In Average Sales Prices Before 2005

The agency’s final 2005 Physician Fee Schedule includes a second round of preliminary ASPs, with data for a larger number of drugs than in the proposed rule. Final average sales prices for the first quarter of 2005 will be published in December.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel